TOP2B Cleavage Complex Stabilization and Persistent Double-Strand Breaks
Primary vascular smooth muscle cells express high baseline levels of topoisomerase IIβ (TOP2B), the essential enzymatic isoform mediating anthracycline-induced vascular and cardiotoxic liabilities, whereas topoisomerase IIα (TOP2A) is largely restricted to actively proliferating cell populations [1][2]. Doxorubicin intercalates into genomic DNA preferentially at 5'-d(CG)-3' dinucleotide motifs, stabilizing covalent TOP2B-DNA cleavage complexes and preventing the re-ligation of phosphodiester bonds during normal enzymatic topological relief [3]. This stabilization converts transient catalytic intermediates into refractory double-strand breaks (DSBs) [3][4]. In primary human aortic vascular smooth muscle cells, treatment with sub-micromolar doxorubicin concentrations (25–100 nM) results in the rapid assembly of macromolecular repair complexes marked by high concentrations of phosphorylated histone variant H2AX (γ-H2AX) and tumor suppressor p53-binding protein 1 (53BP1) [1][2][4].
Unlike transient, radiomimetic breaks that undergo repair within several hours through non-homologous end joining (NHEJ), anthracycline-induced DSBs persist for days [2][4]. Quantitative immunofluorescence reveals retention of more than five co-localized γ-H2AX/53BP1 foci per nucleus five days after drug washout, indicating structural damage that overwhelms endogenous repair systems [4]. As summarized in Table 1, the biological actions of doxorubicin differ fundamentally from catalytic topoisomerase inhibitors and non-genotoxic senescence inducers, initiating stable genomic lesions that stall replication machinery without prompting immediate cytolysis [1][2][3]. The structural stability of these adducts provides the mechanical foundation for sustained DNA damage response (DDR) signaling, ultimately committing vascular smooth muscle cells to premature senescence rather than programmed cell death [1][2].
ATM/Chk2 and p53-p21Cip1 Signaling Cascade Execution
Vascular smooth muscle cell senescence manifests through two biologically distinct trajectories: replicative senescence (RS) driven by gradual telomere attrition, and stress-induced premature senescence (SIPS) triggered by acute genotoxic stress [1]. Replicative senescence requires dozens of cell divisions, proceeding through progressive loss of the protective shelterin component TRF2, uncapping of telomeric ends, and gradual transcriptional derepression of the CDKN2A (p16INK4a) locus [1][5]. In contrast, doxorubicin-induced SIPS is initiated within 24 to 72 hours through telomere-independent activation of the ataxia telangiectasia mutated (ATM) kinase [1][2].
Upon encountering stalled TOP2B cleavage complexes, ATM undergoes autophosphorylation at Ser1981, initiating downstream phosphorylation of the effector kinase Chk2 at Thr68 [2][4]. Activated ATM directly phosphorylates the p53 tumor suppressor protein at Ser15 and Ser20, disrupting binding interactions with the E3 ubiquitin-protein ligase MDM2 and preventing proteasomal destruction of p53 [2][6]. The resulting stabilized tetrameric p53 complex coordinates transcriptional activation of CDKN1A, which encodes the cyclin-dependent kinase inhibitor p21Cip1 [2][6]. Western blot assays demonstrate dose-dependent elevations of p53 and p21Cip1 in vascular cells following doxorubicin exposure [2][6]. Elevated p21Cip1 binds and inhibits cyclin E-CDK2 and cyclin D-CDK4/6 complexes, blocking the phosphorylation of the retinoblastoma protein (pRb) [1][6]. Hypophosphorylated pRb sequesters the E2F transcription factor family, enforcing stable cell-cycle arrest [1]. While p16INK4a protein levels show minor increases at extended time points in SIPS, early and persistent arrest in vascular smooth muscle cells is predominantly driven by the stoichiometry of the ATM-p53-p21Cip1 signaling axis [1][2].
Mitochondrial Redox Cycling and Secondary DNA Lesion Amplification
The persistence of the DNA damage response following doxorubicin exposure cannot be attributed entirely to initial TOP2B entrapment; it is augmented by cyclic generation of reactive oxygen species (ROS) [2][3]. The planar quinone structure of doxorubicin undergoes single-electron reduction catalyzed by mitochondrial respiratory Complex I and endothelial nitric oxide synthase, yielding an unstable semiquinone radical intermediate [3][5]. In aerobic cellular environments, the semiquinone donates its extra electron to molecular oxygen, regenerating the parent quinone while generating superoxide anions (O₂^{\bullet-}) [3]. Superoxide dismutates into hydrogen peroxide (H₂O₂), diffusing throughout the cell and penetrating the nuclear compartment [2][3].
Simultaneously, doxorubicin displaces intracellular iron from storage proteins like ferritin and directly forms coordination complexes with ferric iron (Fe³⁺) [3]. These complexes catalyze iron-mediated Fenton chemistry, reducing H₂O₂ to highly reactive hydroxyl radicals (^{\bulletOH}) [3]. Hydroxyl radicals cause oxidative DNA modifications, characterized by the accumulation of 8-hydroxy-2'-deoxyguanosine (8-OHdG) [1][3]. These secondary oxidative lesions induce widespread single-strand breaks and stall advancing replication forks [3][4]. The constant influx of oxidative stress damages base excision repair (BER) enzymes and induces mitochondrial DNA lesions, initiating an intracellular feed-forward signaling cascade [2][3]. Consequently, flow cytometry assays utilizing carboxy-H2DCFDA reveal sustained elevations in ROS levels within vascular smooth muscle cells lasting up to six days after a brief drug pulse, maintaining DDR kinase activation long after the physical clearance of free anthracycline molecules [2].
Cell-Cycle Exit Topography and Sustained S/G2/M Phase Arrest
Cellular senescence in vascular tissue possesses distinct cell-cycle distribution profiles depending on the initiating stimulus and the operational arrest checkpoints [1][7]. Replicative senescence traps primary cells almost exclusively within the diploid G0/G1 phase of the cell cycle as a consequence of gradual CDK4/6 inhibition [1]. Conversely, doxorubicin exposure causes significant accumulation of cells in the S and G2/M phases, creating a unique cell-cycle topography [4][7]. Live-cell imaging using fluorescent ubiquitination-based cell cycle indicators (FUCCI) demonstrates that cells exposed to low-dose doxorubicin establish durable growth arrest in S and G2 phases, retaining high levels of mAG-Geminin reporter activity without entering mitosis [7]. In human diploid cells, including human foreskin fibroblasts and vascular smooth muscle models, doxorubicin drives irreversible cell-cycle stalling at the G2/M transition [4][7].
This prolonged G2-phase arrest is sustained by persistent ATR/Chk1 and ATM/Chk2 signaling cascades that prevent the activating dephosphorylation of CDK1 (Cdc2) by CDC25C phosphatases [4][6]. In EA.hy926 vascular endothelial cells and smooth muscle populations, prolonged arrest often coincides with endoreplication or nuclear budding, resulting in giant multinucleated cells with high genomic instability [4][6]. Crucially, maintaining doxorubicin concentrations between 25 nM and 100 nM prevents the cleavage of executioner caspase-3 and poly(ADP-ribose) polymerase-1 (PARP-1), averting apoptosis [4]. Instead, the cells enter a non-dividing state characterized by a lack of 5-ethynyl-2'-deoxyuridine (EdU) or bromodeoxyuridine (BrdU) incorporation and high retention of senescence-associated β-galactosidase (SA-β-gal) activity at pH 6.0 [1][2][7].
Contractile-to-Synthetic Phenotypic Switching and Senescence Secretome Induction
The commitment of vascular smooth muscle cells to premature senescence fundamentally alters their structural and functional phenotype [1][2]. Contractile vascular smooth muscle cells maintain arterial compliance and vascular tone through specialized contractile proteins [1]. Sustained DDR signaling suppresses the serum response factor (SRF) and myocardin transcriptional co-activator complex, resulting in down-regulation of essential contractile markers, including smooth muscle α-actin (ACTA2), calponin (CNN1), and transgelin (TAGLN/SM22α) [1]. Doxorubicin-treated cells shift from an elongated, spindle-shaped morphology into a flattened, hypertrophic phenotype with elevated cytoplasmic area, prominent actin stress fibers, and strong lysosomal SA-β-gal staining [1][2].
Concurrently, the cells acquire a senescence-associated secretory phenotype (SASP), converting quiescent structural elements of the vessel wall into pro-inflammatory paracrine hubs [2][5]. Genotoxic stress activates the stress kinase p38 MAPK, which coordinates with sustained non-canonical nuclear factor kappa B (NF-κB) transcription to drive cytokine synthesis [8]. Enzyme-linked immunosorbent assays (ELISA) confirm marked increases in the secretion of interleukin-6 (IL-6), interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF) from senescent vascular smooth muscle cells [2][4]. In MDA-MB-231 and vascular reference systems, senescent secretomes exhibit parallel cytokine enrichment profiles that degrade extracellular matrix integrity and stimulate chronic tissue remodeling [2][4][8]. Elevated matrix metalloproteinases, paired with pro-inflammatory cytokines, compromise local elasticity and induce secondary paracrine senescence in adjacent vascular endothelial and medial cells, linking anthracycline chemotherapy directly to accelerated arterial stiffness and premature vascular aging [1][2][5].